Trial Profile
A Single Center, Open-label, Non-comparative, Phase I/II Clinical Trial to Assess the MTD, Safety and Efficacy of BEY1107 in Monotherapy and in Combination With Gemcitabine in Patient With Locally Advanced or Metastatic Pancreatic Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Avotaciclib (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeyondBio
- 23 Jul 2019 Planned End Date changed from 13 Oct 2021 to 1 Oct 2021.
- 23 Jul 2019 Planned primary completion date changed from 23 Mar 2021 to 1 Mar 2021.
- 16 Jul 2018 New trial record